<DOC>
	<DOCNO>NCT02205333</DOCNO>
	<brief_summary>The main purpose study determine best dose MEDI6469 safe tolerable give monotherapy combination tremelimumab , MEDI4736 , rituximab subject either advance solid tumor diffuse large B-cell lymphoma ( DLBCL ) . Tremelimumab MEDI4736 test MEDI6469 set subject advance solid tumor rituximab test MEDI6469 subject DLBCL . MEDI6469 test monotherapy subject advance solid tumor .</brief_summary>
	<brief_title>A Phase 1b/2 Safety Tolerability MEDI6469 Combination With Therapeutic Immune Agents Monoclonal Antibodies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults &gt; /= 18 year old Histologically cytologically confirm advanced solid tumor refractory standard therapy standard therapy exist ( Monotherapy Cohorts A B ) At least one lesion measurable RECIST previously irradiate ( Monotherapy Cohorts A B ) Histologically confirm DLBCL ( Cohort C ) Adequate organ marrow function ECOG performance status 0 1 Willingness provide consent biopsy sample Prior exposure immunotherapy ( either single agent combination ) include limited CD137 OX40 agonist , antiCTLA4 , antiPD1 , antiPDL1 , antiPDL2 antibody pathwaytargeting agent History organ transplant require use immunosuppressive History primary immunodeficiency tuberculosis Active prior document autoimmune disease within past 3 year Active chronic viral hepatitis history type hepatitis within last 6 month Major surgical procedure within 30 day prior first dose investigational product still recover prior surgery Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Solid tumor</keyword>
	<keyword>Diffuse Large B-cell Lymphoma</keyword>
	<keyword>program death 1</keyword>
	<keyword>program dealth ligand 1</keyword>
	<keyword>cytotoxic T-lymphocyte-associated antigen-4</keyword>
	<keyword>OX40 ligand</keyword>
</DOC>